CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 277.5	$ 342.4
Short-term investments	187.0	157.9
Accounts receivable, net	225.4	243.9
Inventories	476.4	440.4
Other current assets	97.8	91.3
Total current assets	1,264.1	1,275.9
Property, plant and equipment, net	241.0	239.1
Intangibles, net and other long-term assets	334.8	293.4
Total assets	1,839.9	1,808.4
Current liabilities:
Current portion of long-term debt	0.1	20.1
Accounts payable	94.7	86.1
Customer advances	148.9	149.0
Other current liabilities	271.2	269.5
Total current liabilities	514.9	524.7
Long-term debt	384.7	391.6
Other long-term liabilities	208.7	199.0
Commitments and contingencies (Note 10)
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value 260,000,000 shares authorized, 170,636,719 and 170,552,890 shares issued and 159,933,578 and 159,854,695 shares outstanding at March 31, 2017 and December 31, 2016, respectively	1.7	1.7
Treasury stock, at cost, 10,703,141 and 10,698,195 shares at March 31, 2017 and December 31, 2016, respectively	(249.3)	(249.3)
Accumulated other comprehensive loss	(60.2)	(75.9)
Other shareholders' equity	1,032.5	1,009.9
Total shareholders' equity attributable to Bruker Corporation	724.7	686.4
Noncontrolling interest in consolidated subsidiaries	6.9	6.7
Total shareholders' equity	731.6	693.1
Total liabilities and shareholders' equity	$ 1,839.9	$ 1,808.4